Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shan Dong Kexing Bioproducts Co's revenue for the
three
months ended in Mar. 2026 was ¥281 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1,461 Mil.
Shan Dong Kexing Bioproducts Co's Revenue per Share for the
three
months ended in Mar. 2026 was ¥1.41.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥7.31.
During the past 9 years, Shan Dong Kexing Bioproducts Co's highest 3-Year average Revenue per Share Growth Rate was 5.90% per year. The lowest was -23.50% per year. And the median was -6.50% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Shan Dong Kexing Bioproducts Co Revenue Related Terms
Shan Dong Kexing Bioproducts Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688136 vs VRTX, REGN, RVMD: Revenue Comparison
For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shan Dong Kexing Bioproducts Co Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's Revenue distribution charts can be found below:
* The bar in red indicates where Shan Dong Kexing Bioproducts Co's Revenue falls into.
Shan Dong Kexing Bioproducts Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,461 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co (SHSE:688136) has a Revenue of ¥1,461 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Shan Dong Kexing Bioproducts Co and its competitors.
Is Shan Dong Kexing Bioproducts Co's Revenue too high?
Shan Dong Kexing Bioproducts Co's current Revenue is ¥1,461 Mil. Overall, Shan Dong Kexing Bioproducts Co has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shan Dong Kexing Bioproducts Co's Revenue compare to VRTX and REGN?
Shan Dong Kexing Bioproducts Co's Revenue of ¥1,461 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. Shan Dong Kexing Bioproducts Co's current Revenue is ¥1,461 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shan Dong Kexing Bioproducts Co stock overvalued right now?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co (SHSE:688136) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥24.52, compared to a current price of ¥20.56 — trading 16.2% below its estimated fair value. The current Revenue is ¥1,461 Mil. Shan Dong Kexing Bioproducts Co's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Shan Dong Kexing Bioproducts Co (SHSE:688136), the current Revenue is ¥1,461 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shan Dong Kexing Bioproducts Co (SHSE:688136) Overvalued in 2026?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co stock appears to be undervalued.
The current stock price of ¥20.56 is trading 16.2% below its estimated GF Value™ of ¥24.52.
GuruFocus considers Shan Dong Kexing Bioproducts Co to be Modestly Undervalued.
Key valuation signals for SHSE:688136:
Revenue: ¥1,461 Mil
GF Value™: ¥24.52 vs. price of ¥20.56 (16.2% below fair value)
No single metric tells the full story. See the SHSE:688136 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
46GF Score
Get the complete analysis for SHSE:688136
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688136 has been successfully added to your 
